Related Experiment Videos
Atosiban
1Department of Obstetrics and Gynecology, Ohio State University, Columbus 43210-1250, USA.
Abstract:
The role of oxytocin and oxytocin receptors in preterm labor is perhaps more prominent than once thought. The blockade of oxytocin and/or oxytocin receptors has both a theoretical and clinical aspect. Initial trials with the oxytocin antagonist atosiban have been encouraging with respect to efficacy and side effect profile. Current trials are examining the efficacy and dosing regimens of atosiban. Additional work must be done with this drug. However, if subsequent data demonstrate that atosiban is as effective as ritodrine in obtaining uterine quiescence, on the basis of its milder side effect profile, it should be seriously considered as a tocolytic of choice for the treatment of preterm labor. Moreover, it may have significant appeal for combination use with other tocolytics, given its alternative mechanism of action to betamimetics and magnesium sulfate.
Insights
Oxytocin receptor blockade with atosiban shows promise for treating preterm labor. This drug may become a preferred tocolytic due to its efficacy and favorable side effect profile compared to existing treatments.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
- Obstetrics
Background:
- Oxytocin plays a significant role in preterm labor.
- Blocking oxytocin receptors is a potential therapeutic strategy.
Purpose of the Study:
- To evaluate the efficacy and safety of the oxytocin antagonist atosiban for preterm labor.
- To compare atosiban with existing tocolytic agents.
Main Methods:
- Clinical trials investigating atosiban's efficacy.
- Assessment of side effect profiles.
- Examination of optimal dosing regimens.
Main Results:
- Initial trials with atosiban are encouraging regarding efficacy and side effects.
- Further trials are ongoing to confirm effectiveness and dosing.
Conclusions:
- Atosiban demonstrates potential as a tocolytic agent for preterm labor.
- Its milder side effect profile may make it preferable to ritodrine.
- Atosiban could be valuable for combination therapy with other tocolytics.